Compass Capital Management Inc. lowered its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 167,427 shares of the medical technology company’s stock after selling 2,666 shares during the quarter. Stryker makes up about 3.5% of Compass Capital Management Inc.’s holdings, making the stock its 6th biggest position. Compass Capital Management Inc.’s holdings in Stryker were worth $66,239,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently modified their holdings of the company. Mid American Wealth Advisory Group Inc. purchased a new stake in Stryker in the second quarter valued at $26,000. Sachetta LLC increased its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares in the last quarter. Ridgewood Investments LLC lifted its holdings in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Stryker in the 1st quarter valued at about $37,000. Finally, Solstein Capital LLC purchased a new position in Stryker during the 2nd quarter worth approximately $43,000. 77.09% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Stryker
In other news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 520,500 shares of company stock worth $184,803,065 over the last 90 days. Insiders own 5.90% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Analysis on Stryker
Stryker Trading Up 0.5%
NYSE SYK opened at $355.74 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $136.04 billion, a P/E ratio of 47.12, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The firm has a 50-day moving average price of $374.63 and a 200 day moving average price of $381.38.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.
Stryker Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Recommended Stories
- Five stocks we like better than Stryker
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Big Earnings Misses: Is It Time to Buy the Dip?
- Best Aerospace Stocks Investing
- Is Robinhood’s 11% Post-Earnings Fall a Buy-the-Dip Opportunity?
- What is Short Interest? How to Use It
- AI Demand Is Coming—Is Microchip Technology Ready?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
